Education
About Us
Working with TipRanks
Follow Us
Tonix Pharmaceuticals (TNXP)
NASDAQ:TNXP
TNXP Stock Chart & Stats
$15.08
-$0.02(-7.15%)
At close: 4:00 PM EST
$15.08
-$0.02(-7.15%)
Day’s Range― - ―
52-Week Range$6.76 - $69.97
Previous CloseN/A
Volume36.66M
Average Volume (3M)518.25K
Market Cap
$196.42M
Enterprise Value$0.00
Total Cash (Recent Filing)$190.06M
Total Debt (Recent Filing)$425.00K
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Mar 16, 2026EPS Estimate
-3.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.59
Shares Outstanding12,788,069
10 Day Avg. Volume463,294
30 Day Avg. Volume518,250
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.53
Price to Sales (P/S)7.40
P/FCF Ratio-1.22
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$67.50Price Target Upside347.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Tonix Pharma News
TNXP FAQ
What was Tonix Pharmaceuticals’s price range in the past 12 months?
Tonix Pharmaceuticals lowest stock price was $6.76 and its highest was $69.97 in the past 12 months.
What is Tonix Pharmaceuticals’s market cap?
Tonix Pharmaceuticals’s market cap is $196.42M.
When is Tonix Pharmaceuticals’s upcoming earnings report date?
Tonix Pharmaceuticals’s upcoming earnings report date is Mar 16, 2026 which is in 66 days.
How were Tonix Pharmaceuticals’s earnings last quarter?
Tonix Pharmaceuticals released its earnings results on Nov 10, 2025. The company reported -$3.59 earnings per share for the quarter, missing the consensus estimate of -$3.585 by -$0.005.
Is Tonix Pharmaceuticals overvalued?
According to Wall Street analysts Tonix Pharmaceuticals’s price is currently Undervalued.
Does Tonix Pharmaceuticals pay dividends?
Tonix Pharmaceuticals does not currently pay dividends.
What is Tonix Pharmaceuticals’s EPS estimate?
Tonix Pharmaceuticals’s EPS estimate is -3.19.
How many shares outstanding does Tonix Pharmaceuticals have?
Tonix Pharmaceuticals has 12,788,069 shares outstanding.
What happened to Tonix Pharmaceuticals’s price movement after its last earnings report?
Tonix Pharmaceuticals reported an EPS of -$3.59 in its last earnings report, missing expectations of -$3.585. Following the earnings report the stock price went up 4.097%.
Which hedge fund is a major shareholder of Tonix Pharmaceuticals?
Currently, no hedge funds are holding shares in TNXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tonix Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$67.50 (347.61% Upside)
$67.50 (347.61% Upside)
Blogger Sentiment
Bullish
TNXP Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 4.2%
Last 30 Days ▲ 4.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.74%
12-Months-Change
Fundamentals
Return on Equity
-64.99%
Trailing 12-Months
Asset Growth
165.76%
Trailing 12-Months
Company Description
Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
TNXP Stock 12 Month Forecast
Average Price Target
$67.50
▲(347.61% Upside)
Technical Analysis
Ownership Overview
0.04% Insiders
6.22% Mutual Funds
0.63% Other Institutional Investors
85.74% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---